Insulet, GSK ink distribution deal

Insulet Corporation and GlaxoSmithKline have announced an exclusive distribution agreement for the OmniPod insulin management system in Canada. The OmniPod system is the world's first tubing-free insulin pump and has just two components: the small, waterproof pod that can be worn on many parts of the body, and the personal diabetes manager, a handheld device that communicates wirelessly to program the pod, according to an Insulet statement.

Under the terms of the agreement, GSK will have exclusive rights to promote, advertise, market, distribute and sell the OmniPod System in the country. Additional information for Canadian patients and healthcare providers will soon be available at www.myomnipod.ca, which is currently scheduled to launch in mid-March.

"The OmniPod's tubing-free design and ease of use have provided freedom to tens of thousands of people in the United States and abroad," says Duane DeSisto, president and CEO of Insulet. "We look forward to the opportunity to positively impact the lives of Canadians with insulin-dependent diabetes."

- get the Insulet statement

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.